Compare Progressive Corp (PGR) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

PGR trades at $213.46, down 3.1% on the day, amid mixed earnings results with recent Q3 2026 miss. The stock shows strong fundamentals with revenue growth from $49.6B in 2022 to $87.6B in 2025 and net income margin of 12.85%. Technicals are bullish with moving averages supporting upside, while RSI levels indicate potential overbought conditions. Recent news highlights Progressive's telematics edge and inclusion in dividend-focused articles.

Outlook remains positive with analyst consensus target of $222.23 implying ~4% upside. Key opportunities include sustained underwriting strength and dividend reliability, but risks involve competitive pressures in auto insurance and earnings volatility. The stock's valuation at P/E of 11.18 appears reasonable relative to profitability metrics.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.